与「OncoAlert」相关的搜索结果

❓️ PROTEUS Trial - thoughts? A Letter to the Editor & an editorial pubished in EUO ➡️ PROTEUS: A Practice-changing Trial, but Are We Ready to Embrace Perioperative Apalutamide for All High-risk Patients? by Giuseppe Di Lorenzo & Francesco Montorsi @profmontorsi ➡️ PROTEUS Trial the Day After: Practice Changing or Premature Escalation? by Isabel Heidegger...Pierre Blanchard et al @heid58187 ➡️ Thank you to the authors for sharing their valuable insights! @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

PSMA PET/CT–Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study In this prospective single-center study of 63 men with negative or equivocal mpMRI (PI-RADS 2–3), PSMA PET/CT–guided targeted biopsy 💉 significantly outperformed systematic biopsy for detecting clinically significant #ProstateCancer# (37% vs. 21%). Combining both approaches further improved detection. SUVmax independently predicted clinically significant disease, while dynamic total-body PET kinetic parameters enhanced lesion characterization, particularly in equivocal cases. These findings support PSMA PET/CT as a valuable adjunct for biopsy guidance and risk stratification. @andrea_farolfi @stefanofanti4 @riccardoschiav6 @drMDrog @OncoAlert 🚨 #LPCCC27# @Silke_Gillessen @AOmlin @ProfKHerrmann Jochen Walz @weoncologists

📌FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer @OncoAlert #OncoAlertAF#

Introducing #APCCC26# Live from Lugano🇨🇭Brought to you from APCCC together with @OncoAlert 🚨 Triplet vs Doublet Therapy in Metastatic Hormone-Sensitive Prostate Cancer | APCCC 2026 Expert Discussion Join Dr. Jones, Dr. Rathkopf, and Dr. Fizazi for an expert discussion on one of the most rapidly evolving questions in genitourinary oncology: the optimal treatment approach for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Series Faculty @BertrandTOMBAL @ChrisSweens1 @jmmrad @drjefstathiou @CaPsurvivorship @LoebStacy @charlesryanmd @AarmstrongDuke @Ecastromarcos @LVM_Walz @piet_ost @Nicola_Fossati @AnthonyMJoshua @Prof_Nick_James @VedangMurthy @AttardLab @Silke_Gillessen @AOmlin Pinging @AmandaNizamMD @scocmem @nataliagandur @gu_onc @tompowles1 @brian_rini @declangmurphy @cdanicas @neerajaiims